Clin2
NCT07263230Possibly a fitRecruiting

Roflumilast Foam for Hidradenitis Suppurativa

Hidradenitis Suppurativa (HS)

Treatments studied

Part of Infections, Skin clinical trials.

This study tests whether roflumilast foam (a prescription foam) is safe and can reduce inflamed bumps in people with mild-to-moderate hidradenitis suppurativa (HS) who do not have draining tunnels. Participants will stop other HS treatments during the trial.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have had hidradenitis suppurativa (HS) for at least 3 months.
  • Your HS should be mild to moderate (Hurley stage I or II) with 4 to 10 inflamed bumps (abscesses and nodules) but no draining tunnels.
  • You must agree to stop using antibiotics, steroid injections, and certain medicated washes on your HS for the study.
  • If you are a woman who could become pregnant, you must have a negative pregnancy test and use birth control.
  • You cannot have a history of severe depression, suicidal thoughts or behavior.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07689188Not yet recruiting· Phase 2
Roflumilast foam for hidradenitis suppurativa

This trial tests a new foam containing roflumilast (a medicine that reduces inflammation) for people with hidradenitis suppurativa (HS). It aims to see if the foam can safely reduce painful lumps and improve HS symptoms.

Missouri City, Texas
NCT06645821Recruiting· Early Phase 1
Cream for mild to moderate hidradenitis suppurativa

This trial tests a new cream (EVO101) for people with mild to moderate hidradenitis suppurativa (HS), a skin condition causing painful lumps. It aims to see if the cream can reduce the number of lesions. Participants cannot use certain other HS treatments during the study.

Norfolk, Virginia
NCT06932003Recruiting· Phase 1/Phase 2
Testing a new tablet for hidradenitis suppurativa

This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.

Beijing, Beijing Municipality
NCT07244510Recruiting· Phase 2
New Treatment for Moderate to Severe Hidradenitis Suppurativa

This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.

Samsun, Turkey
NCT07554014Not yet recruiting· Phase 4
New injectable treatment with laser for hidradenitis suppurativa

This study tests a combination of an injection (anti-IL-17A/F monoclonal antibody) and a special laser treatment for hidradenitis suppurativa (HS), a painful skin condition with recurring lumps and abscesses. You'll be followed closely to see if this combination helps reduce your symptoms and improves your skin.

Hangzhou, Zhejiang
NCT07155239Recruiting· Phase 1
Laser treatment for hidradenitis suppurativa (acne inversa)

This trial tests a 1726-nm laser to reduce inflamed nodules in people with mild to moderate hidradenitis suppurativa (HS). It compares treated and untreated areas to see if the laser helps without affecting the rest of the body.

Rosemead, California

Hear when a new Hidradenitis Suppurativa (HS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.